Extension of Time to File SOU

BASAGLAR

Eli Lilly and Company

Trademark/Service Extension of Time

PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 85350709
LAW OFFICE ASSIGNED LAW OFFICE 116
MARK SECTION
MARK BASAGLAR
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT BASAGLAR
OWNER SECTION
NAME Eli Lilly and Company
STREET Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
COUNTRY United States
PHONE 317-276-9624
FAX 317-276-1919
EMAIL XXXX
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants
GOODS OR SERVICES DELETED FROM THE APPLICATION antipsychotic pharmaceutical preparations;
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 12/27/2011
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT 150
TOTAL AMOUNT 150
SIGNATURE SECTION
SIGNATURE /reljr44/
SIGNATORY'S NAME Robert E. Lee, Jr.
SIGNATORY'S POSITION Assistant General Patent Counsel
DATE SIGNED 04/26/2012
SIGNATORY'S PHONE NUMBER 317 276 9624
FILING INFORMATION
SUBMIT DATE Thu Apr 26 17:04:27 EDT 2012
TEAS STAMP USPTO/ESU-XX.XXX.XX.XX-20
120426170427719094-853507
09-4906d42275adb3296de625
867adb11d3-DA-4388-201204
25185516376673



PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: BASAGLAR
SERIAL NUMBER: 85350709

The applicant, Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/27/2011.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are permanently deleted from this application: antipsychotic pharmaceutical preparations;

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants

This is the first extension request.



A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.


Declaration

The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements may jeopardize the validity of the form or any resulting registration, declares that he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the applicant to be the owner of the trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on information and belief are believed to be true.


Signature: /reljr44/      Date Signed: 04/26/2012
Signatory's Name: Robert E. Lee, Jr.
Signatory's Position: Assistant General Patent Counsel
Signatory's Phone: 317 276 9624

RAM Sale Number: 4388
RAM Accounting Date: 04/27/2012

Serial Number: 85350709
Internet Transmission Date: Thu Apr 26 17:04:27 EDT 2012
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XX-20120426170427719
094-85350709-4906d42275adb3296de625867ad
b11d3-DA-4388-20120425185516376673



Extension of Time to File SOU [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed